CytomX Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $33,432 | $25,115 | $41,463 | $26,607 |
Gross Profit | 33,432 | 24,656 | 40,996 | 26,121 |
EBITDA | 4,540 | -8,452 | 12,124 | -120 |
EBIT | 4,111 | -8,911 | 11,657 | -606 |
Net Income | 5,736 | -6,534 | 13,791 | 837 |
Net Change In Cash | 33,432 | 25,115 | 41,463 | 26,607 |
Free Cash Flow | -20,748 | -19,645 | -26,160 | -22,229 |
Cash | 40,576 | 43,247 | 36,185 | 17,171 |
Basic Shares | 85,204 | 84,880 | 82,630 | 67,310 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $101,214 | $53,163 | $69,573 | $100,362 |
Gross Profit | 101,214 | 53,163 | 69,573 | 100,362 |
EBITDA | -4,309 | -98,892 | -81,075 | -77,967 |
EBIT | -6,484 | -101,335 | -83,781 | -83,427 |
Net Income | -569 | -97,299 | -80,648 | -32,885 |
Net Change In Cash | 101,214 | 53,163 | 69,573 | 100,362 |
Cost of Revenue | 13,671 | 13,671 | 3,434 | |
Free Cash Flow | -56,875 | -112,528 | -120,640 | 2,950 |
Cash | 17,171 | 193,650 | 205,530 | 191,859 |
Basic Shares | 73,808 | 65,739 | 64,146 | 46,145 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.07 |
2024-06-30 | -$0.08 |
2024-03-31 | $0.17 |
2023-12-31 | $0.01 |
